Estrogen receptor (ER)-positive breast cancer accounts for 70% of breast cancer subtypes and, despite its relatively good prognostic tumor biology, harbors a substantial and constant risk of recurrence after the primary resection, even after five years of treatment [1,2,3]. This evidence concerns the gene ESR1 and breast cancer.